Ana deCarvalho

Ana deCarvalho

Staff Scientist - Department of Neurosurgery Henry Ford Hospital

Ana deCarvalho

Office Phone



 Research Interests

  • Clonal evolution, genomic heterogeneity, and response to therapy in tumors and patient-derived models of high grade glioma
  • Mechanisms of resistance, target validation, and combination therapies for glioblastoma
  • Developmental programs aberrantly activated in high grade gliomas as key drivers of plasticity, transient cancer stem cell phenotype and drug resistance

Research description

High grade astrocytomas are the most prevalent and aggressive central nervous system tumors in the adult population. Despite intensive treatment comprised of surgical resection, radiation and cytotoxic chemotherapy, prognosis is still unfavorable. Mechanisms of resistance to therapy include drug delivery to the brain, molecular diversity among tumors sharing the same histological grade, intratumoral heterogeneity, and lack of predictive biomarkers. The Hermelin Brain Tumor Center at Henry Ford Hospital has one of the largest brain tumor biorepositories in the world, and contributed significantly to The Cancer Genome Project (TCGA). My lab has leveraged this resource to create a panel of cancer stem-like cells from freshly resected high grade gliomas covering in depth the main genomic abnormalities encountered in the clinic. These cells are used for in vitro studies and also to establish patient-derived orthotopic tumor xenografts in mice (PDX).
Using these models, we are investigating how the developmental programs aberrantly activated in high grade gliomas drive plasticity and heterogeneity, leading to a transient “cancer stem cell” phenotype, and contributing to drug resistance. Sox2 and MET-activated pathways are currently being studied.

To further validate the models, we are investigating the consequences of changes in selective pressure on neoplastic cells in the different microenvironments: from the original tumor, to dissociated cells in culture, and to the mouse brain. By employing exome sequencing, low pass whole genome sequencing, RNAseq, targeted proteomics and FISH, we access preservation of clonal driver genomic alterations, occurrence of clonal evolution, and changes in gene expression and signaling pathways. We are especially interested in the effect of the microenvironment on extrachromosomal DNA amplification.

The PDXs are enrolled in pre-clinical trials testing the anti-tumor efficacy of compounds in early development or already in clinical trials. The treatment efficacy results are integrated with pre-treatment molecular profiling to identify biomarkers of response. By studying how therapy-driven genomic and phenotypic alterations contribute to resistance, new combination therapies can be proposed and tested in the models. It is expected that the results of these studies with relevant models of high grade glioma will better inform future clinical trials, including the stratification of patients to the most appropriate therapies. We are currently focusing in particular on the molecular correlates of sensitivity of high grade gliomas to the inhibition of serine/threonine kinases mTOR and DNA-PK.


B.Sc. School of Engineering, Campinas State University, Campinas, SP, Brazil, 1991

Ph.D, Department of Biological Sciences, Florida State University, Tallahassee, FL, 2001


Selected Publications:

  • Quartararo CE, Reznik E, deCarvalho AC, Mikkelsen T, Stockwell BR. (2015) High-throughput screening of patient-derived cultures reveals potential for precision medicine in glioblastoma. ACS Med Chem Lett. 6(8):948-952 (PMID: 26288699)
  • Mueller C, deCarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V, Liotta LA, Petricoin III EF (2014) Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Research, 74(3):818-828 (PMID: 24346432)
  • Lubanska D, Market-Velker BA, deCarvalho AC, Mikkelsen T, Silva EF, Porter LA. (2014) The Cyclin-Like Protein Spy1 Regulates Growth and Division Characteristics of the CD133+ Population in Human Glioma. Cancer Cell, 25(1):64-76 (PMID: 24434210)
  • Berezovsky AD, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, Hong X, Hasselbach LA, Irtenkauf SM, Mikkelsen T, deCarvalho AC. (2014) Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. Neoplasia, 16(3):193-206 (PMID: 24726753) COVER ARTICLE
  • Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. (2014) Mechanisms of glioma formation: Iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 16(7):543-561 (PMID: 25117977)
  • Hasselbach LA, Irtenkauf SM, Lemke NW, Nelson KK, Berezovsky AD, Carlton ET, Transou AD, Mikkelsen T, deCarvalho AC (2014). Optimization of high grade glioma cell culture from surgical specimens for use in clinically relevant animal models and 3D immunocytochemistry Journal of Visualized Experiments, 83:e51088 (PMID: 24429465)
  • deCarvalho AC, Lehman NL, Mikkelsen T. (2013) Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy. Current Signal Transduction Therapy, 8(1): 3-13
  • deCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis SN, Mikkelsen T. (2010) Gliosarcoma Stem Cells Undergo Glial and Mesenchymal Differentiation In Vivo. Stem Cells, 28(2):181–190 (PMID: 19937755)

Faculty Status

Cancer Biology

← Return to listing